News

San Antonio biotech acquires U.K. wound-care company

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare ...

Kiromic founder says Houston biotech’s move to SA nearly a done deal

Houston-based immunotherapy company Kiromic is expected this month to approve moving its headquarters ...

Events

4th Annual SURF 2018

What: San Antonio Military Health System and Universities ResearchForum When: Thursday, June ...

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
News
Biotech firm completes study on skin wart treatment
February 20, 2014

By Mike W. Thomas, San Antonio Business Journal

Local biotech firm ViroXis Corp. is wrapping up a Phase 2 clinical study of its treatment for a virus that causes skin warts.

The final patient of the 183-person enrolled study has completed treatment and the results will be known once the data has been analyzed. ViroXis has developed a drug for treating the Human Papilloma Virus (HPV) using oils from the East Indian Sandalwood tree. The study is being funded by the proceeds of a $5 million Series B private offering.

ViroXis also announced plans to initiate a second Phase 2 clinical study in a new direction to test its effect on Molluscum contagiosum (MCV) in a pediatric population. MCV is a highly contagious pox virus skin infection for which there are currently no approved prescription treatments.

"ViroXis has quickly emerged as leader in the development of botanical drug products, a new and important group of drug candidates afforded a distinct approval process by the (Food and Drug Administration)," says Ian Clements, CEO of ViroXis.

 

Stay informed. Subscribe to BioMed SA news alerts.